#LCSM Chat Topic 07-Oct-2021: Best in Show–Lung Cancer Highlights from #WCLC21 & #ESMO21

Two premier oncology professional organizations, ESMO (European Society for Medical Oncology) and IASLC (International Association for the Study of Lung Cancer), held meetings in September.  On Thursday, October 7, at 8 pm Eastern Time (5 pm Pacific), #LCSM Chat will discuss major lung cancer findings from IASLC 2021 World Conference on Lung Cancer (#WCLC21) and the ESMO 2021 Annual Meeting (#ESMO21). We will examine #WCLC21 and #ESMO21 presentations that could have major impacts on lung cancer clinical care, and why these are important to the lung cancer community. Our moderator Charu Aggarwal… Read More

#LCSM Chat Topic 5/7/2020: #COVID19 testing and #lungcancer: Where we stand today

The COVID-19 pandemic is scary, and the situation continues to evolve.  Lung cancer patients and families may have little understanding of COVID-19 testing or how it may affect patient care.  And there is plenty of confusion out there! For our next chat, “COVID-19 testing and lung cancer: Where we stand today,” we will discuss these concerns with pulmonary pathologists and molecular pathologists, who are on the cutting edge of COVID-19 test development and use. Please join #LCSM Chat Thursday, May 7, 2020, at 8 pm Eastern time (5 pm Pacific) to discuss… Read More

#CANCERSM Chat topic 11-Jul-2019: Basics of Biomarker Testing

Until just a few years ago, chemotherapy was often the only option for some cancer patients.  In just a few short years, molecular therapies and immunotherapies have become commonplace as treatments for cancer patients.  But determining whether a particular cancer patient is a candidate for these new, often very expensive, molecular and immunotherapies requires molecular biomarker testing.  For many cancer patients and their families, the role of molecular biomarker testing in their diagnosis is a unfamiliar and confusing.  How is testing performed?  How is the test result analyzed? What is involved in… Read More